Latest Diabetes News

Argenica Therapeutics has won up to $1.5 million in non-dilutive government funding to support its late-stage clinical trial of ARG-007, a promising treatment for acute ischaemic stroke.

Proteomics International has launched PromarkerD, a pioneering blood test that predicts diabetic kidney disease years before symptoms, marking its entry into the vast US healthcare market.

Recce Pharmaceuticals has locked in a non-dilutive A$30 million debt facility with Avenue Capital Group, extending its cash runway to support pivotal Phase 3 trials and commercialisation of its synthetic anti-infective R327G.

Proteomics International has completed a $12 million capital raise, including a heavily oversubscribed Share Purchase Plan, to fast-track the rollout of its innovative diagnostic tests in Australia and the USA.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.

Zelira Therapeutics has published full results from a Phase I study showing its cannabinoid-based therapy ZLT-L-007 significantly outperforms Lyrica® in managing diabetic neuropathy pain and related symptoms.

Recce Pharmaceuticals has successfully raised A$8.4 million through an entitlement offer and placement to fund pivotal Phase 3 clinical trials, advancing its synthetic anti-infective pipeline towards commercialisation in 2026.

PolyNovo’s NovoSorb BTM technology has demonstrated promising first-in-human results as a novel delivery platform for pancreatic islet cell transplants in Type 1 diabetes, potentially redefining treatment approaches.

Universal Biosensors reported a 6% increase in revenue for Q1 2025 but posted a net loss of A$3.84 million, with cash reserves sufficient only through Q3 2025, raising questions about its financial sustainability.

Universal Biosensors reports a 6% sales increase in Q1 2025, driven by strong growth in wine and veterinary biosensors, while preparing to launch its innovative water testing product later this year.